beta

AGEN

Agenus Inc.

Agen

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 03-13-2019 11-06-2018 08-09-2018 05-07-2018 03-15-2018 11-07-2017 08-03-2017 05-04-2017
Actual EPS -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.29 -0.24 -0.42 -0.35 -0.37 -0.32 -0.18
Consensus EPS -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.25 -0.38 -0.28 -0.28 -0.37 -0.36 -0.32
Estimated EPS -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.28 -0.25 -0.38 -0.28 -0.28 -0.37 -0.36 -0.32
Number of Estimates 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
EPS Surprise -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.04 $0.14 -$0.14 -$0.07 $0.04 $0.14

Stats

Summary

Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

Market Cap: 375 Million

Primary Exchange: NASDAQ Capital Market

Website: http://www.agenusbio.com

Shares Outstanding: 100 Million

Float: 92.6 Million

Dividend: 0.0 (0.0%)

Beta: 2.099262

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 9.25 Million

Ethical Flags

Animal testing

Longest drawdown: 1003 trading days

From: 2015-06-17 To: 2019-06-12

Lowest Point:

Agenus to Host Annual Meeting of Stockholders

via: PR Newswire at 2019-06-13 11:48:00:000

LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stoc… read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

via: PR Newswire at 2019-05-30 04:00:00:000

MARIETTA, Ga. , May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) (" MiMedx " or the " Company "), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announcedthat the Company's board of directors (the " Board ") has a… read more...

MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

via: PR Newswire at 2019-05-30 04:00:00:000

MARIETTA, Ga. , May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) (" MiMedx " or the " Company "), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announcedthat the Company's board of directors (the " Board ") has a… read more...

MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

via: PR Newswire at 2019-05-30 04:00:00:000

MARIETTA, Ga. , May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) (" MiMedx " or the " Company "), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announcedthat the Company's board of directors (the " Board ") has a… read more...

XOMA Corporation: Royalty Aggregation Strategy Likely To Pay Off

via: SeekingAlpha at 2019-05-15 16:04:14:000

Shares of XOMA Corporation (XOMA) have lost over 90% of their value during the past 10 years and are in the red by roughly 30% in the past 12 months. In 2018, it was noted that, since formation (in 1981), the company burned through an astounding $1.2 billion of capital and failed to bring a dr… read more...

XOMA Corporation: Royalty Aggregation Strategy Likely To Pay Off

via: SeekingAlpha at 2019-05-15 16:04:14:000

Shares of XOMA Corporation (XOMA) have lost over 90% of their value during the past 10 years and are in the red by roughly 30% in the past 12 months. In 2018, it was noted that, since formation (in 1981), the company burned through an astounding $1.2 billion of capital and failed to bring a dr… read more...

XOMA Corporation: Royalty Aggregation Strategy Likely To Pay Off

via: SeekingAlpha at 2019-05-15 16:04:14:000

Shares of XOMA Corporation (XOMA) have lost over 90% of their value during the past 10 years and are in the red by roughly 30% in the past 12 months. In 2018, it was noted that, since formation (in 1981), the company burned through an astounding $1.2 billion of capital and failed to bring a dr… read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-09 08:53:19:000

Agenus, Inc. (AGEN) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Jennifer Buell Chief Operating Officer Garo Armen Chairman and Chief Executive Officer Dhan Chand Senior Scientist Bruno Lucidi Chief Executive O… read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-09 08:53:19:000

Agenus, Inc. (AGEN) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Jennifer Buell Chief Operating Officer Garo Armen Chairman and Chief Executive Officer Dhan Chand Senior Scientist Bruno Lucidi Chief Executive O… read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-09 08:53:19:000

Agenus, Inc. (AGEN) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Jennifer Buell Chief Operating Officer Garo Armen Chairman and Chief Executive Officer Dhan Chand Senior Scientist Bruno Lucidi Chief Executive O… read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

TPR, AGEN among premarket gainers

via: SeekingAlpha at 2019-05-09 05:13:59:000

Control4 (NASDAQ: CTRL ) +40% on Q1 earnings . More news on: Control4 Corporation, The Stars Group Inc., Tapestry, Inc., Stocks on the move, Read more … read more...

Agenus +7% on Q1 beat

via: SeekingAlpha at 2019-05-09 04:56:38:000

Agenus ( AGEN ) Q1 results : Revenues: $80M. More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus +7% on Q1 beat

via: SeekingAlpha at 2019-05-09 04:56:38:000

Agenus ( AGEN ) Q1 results : Revenues: $80M. More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus +7% on Q1 beat

via: SeekingAlpha at 2019-05-09 04:56:38:000

Agenus ( AGEN ) Q1 results : Revenues: $80M. More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus beats by $0.41, beats on revenue

via: SeekingAlpha at 2019-05-09 03:32:24:000

Agenus (NASDAQ: AGEN ): Q1 GAAP EPS of $0.12 beats by $0.41 . More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus beats by $0.41, beats on revenue

via: SeekingAlpha at 2019-05-09 03:32:24:000

Agenus (NASDAQ: AGEN ): Q1 GAAP EPS of $0.12 beats by $0.41 . More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus beats by $0.41, beats on revenue

via: SeekingAlpha at 2019-05-09 03:32:24:000

Agenus (NASDAQ: AGEN ): Q1 GAAP EPS of $0.12 beats by $0.41 . More news on: Agenus Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

via: PR Newswire at 2019-05-09 03:30:00:000

LEXINGTON, Mass. , May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided corporate updates and reported financial results for the first quarter of 2… read more...

Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

via: PR Newswire at 2019-05-09 03:30:00:000

LEXINGTON, Mass. , May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided corporate updates and reported financial results for the first quarter of 2… read more...

Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

via: PR Newswire at 2019-05-09 03:30:00:000

LEXINGTON, Mass. , May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided corporate updates and reported financial results for the first quarter of 2… read more...

Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-05-03 09:38:00:000

LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market op… read more...

Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-05-03 09:38:00:000

LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market op… read more...

Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-05-03 09:38:00:000

LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market op… read more...

Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-05-03 09:38:00:000

LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market op… read more...

Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-05-03 09:38:00:000

LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market op… read more...

Bicycle Therapeutics IPO: A Nobel Laureate Founded The Company

via: SeekingAlpha at 2019-05-02 04:15:40:000

Founded by a Nobel prize winner, Bicycle Therapeutics ( BCYC ) has developed a large amount of intangible assets, which should interest investors. Besides, the company reports collaboration agreements with larger pharmaceutical institutions, cash in hand, and no debt. While Bicycle is still at… read more...

Bicycle Therapeutics Files For U.S. IPO

via: SeekingAlpha at 2019-04-29 10:36:34:000

Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c… read more...

Bicycle Therapeutics Files For U.S. IPO

via: SeekingAlpha at 2019-04-29 10:36:34:000

Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c… read more...

Bicycle Therapeutics Files For U.S. IPO

via: SeekingAlpha at 2019-04-29 10:36:34:000

Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c… read more...

Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

via: PR Newswire at 2019-04-02 04:30:00:000

LEXINGTON, Mass. , April 2, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , today announced that the first patient was dosed in the clinical trial &#xA0… read more...

Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

via: PR Newswire at 2019-04-02 04:30:00:000

LEXINGTON, Mass. , April 2, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , today announced that the first patient was dosed in the clinical trial &#xA0… read more...

Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

via: PR Newswire at 2019-04-02 04:30:00:000

LEXINGTON, Mass. , April 2, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , today announced that the first patient was dosed in the clinical trial &#xA0… read more...

Agenus Announces Clinical Appointments

via: PR Newswire at 2019-03-21 05:00:00:000

LEXINGTON, Mass. , March 21, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced new leadership appointments as its CTLA-4 and PD-1 programs advanc… read more...

Agenus Announces Clinical Appointments

via: PR Newswire at 2019-03-21 05:00:00:000

LEXINGTON, Mass. , March 21, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced new leadership appointments as its CTLA-4 and PD-1 programs advanc… read more...

Agenus Announces Clinical Appointments

via: PR Newswire at 2019-03-21 05:00:00:000

LEXINGTON, Mass. , March 21, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced new leadership appointments as its CTLA-4 and PD-1 programs advanc… read more...

Agenus Inc.'s (AGEN) CEO Garo Armen on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-14 08:01:02:000

Agenus Inc. (AGEN) Q4 2018 Results Earnings Conference Call March 14, 2019, 08:30 AM ET Company Participants Jennifer Buell - Chief Operating Officer Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Vice President of Clinical Development Christine Klaskin - Vice… read more...

Agenus Inc.'s (AGEN) CEO Garo Armen on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-14 08:01:02:000

Agenus Inc. (AGEN) Q4 2018 Results Earnings Conference Call March 14, 2019, 08:30 AM ET Company Participants Jennifer Buell - Chief Operating Officer Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Vice President of Clinical Development Christine Klaskin - Vice… read more...

Agenus Inc.'s (AGEN) CEO Garo Armen on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-14 08:01:02:000

Agenus Inc. (AGEN) Q4 2018 Results Earnings Conference Call March 14, 2019, 08:30 AM ET Company Participants Jennifer Buell - Chief Operating Officer Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Vice President of Clinical Development Christine Klaskin - Vice… read more...

Agenus down 5% on Q4 results

via: SeekingAlpha at 2019-03-14 04:13:56:000

Agenus ( AGEN ) Q4 results : Revenues: $6.5M (-23.5%). More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Agenus down 5% on Q4 results

via: SeekingAlpha at 2019-03-14 04:13:56:000

Agenus ( AGEN ) Q4 results : Revenues: $6.5M (-23.5%). More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Agenus down 5% on Q4 results

via: SeekingAlpha at 2019-03-14 04:13:56:000

Agenus ( AGEN ) Q4 results : Revenues: $6.5M (-23.5%). More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Agenus misses by $0.12, misses on revenue

via: SeekingAlpha at 2019-03-14 04:04:00:000

Agenus (NASDAQ: AGEN ): Q4 GAAP EPS of -$0.40 misses by $0.12 . More news on: Agenus Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Agenus misses by $0.12, misses on revenue

via: SeekingAlpha at 2019-03-14 04:04:00:000

Agenus (NASDAQ: AGEN ): Q4 GAAP EPS of -$0.40 misses by $0.12 . More news on: Agenus Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Agenus misses by $0.12, misses on revenue

via: SeekingAlpha at 2019-03-14 04:04:00:000

Agenus (NASDAQ: AGEN ): Q4 GAAP EPS of -$0.40 misses by $0.12 . More news on: Agenus Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more … read more...

Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2019-03-14 04:00:00:000

LEXINGTON, Mass. , March 14, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the fourth qu… read more...

Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2019-03-14 04:00:00:000

LEXINGTON, Mass. , March 14, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the fourth qu… read more...

Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2019-03-14 04:00:00:000

LEXINGTON, Mass. , March 14, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the fourth qu… read more...

Agenus Milestone Triggers $7.5M Payment from Gilead

via: PR Newswire at 2019-03-13 04:30:00:000

LEXINGTON,Mass., March 13,2019 /PRNewswire/ -- Agenus Inc.(NASDAQ: AGEN), an immuno-oncology(I-O) companywith apipelineofimmunecheckpointantibodies, cancer vaccinesandadoptive celltherapies 1 ,announced… read more...

Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-03-08 04:00:00:000

LEXINGTON, Mass. , March 8, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results bef… read more...

Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-03-08 04:00:00:000

LEXINGTON, Mass. , March 8, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results bef… read more...

Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-03-08 04:00:00:000

LEXINGTON, Mass. , March 8, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results bef… read more...

Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-03-08 04:00:00:000

LEXINGTON, Mass. , March 8, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results bef… read more...

Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast

via: PR Newswire at 2019-03-08 04:00:00:000

LEXINGTON, Mass. , March 8, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its fourth quarter and full year 2018 financial results bef… read more...

Agenus Melts Down With Blockchain

via: SeekingAlpha at 2019-02-26 11:12:20:000

Agenus ( AGEN ) is a biotechnology pharmaceutical company with one commercial product and a broad pipeline of potential therapies. It has licensed potential cancer therapies to several larger pharmaceutical companies. The stock plummeted last week, from $3.63 on the prior Friday and to close a… read more...

Agenus Melts Down With Blockchain

via: SeekingAlpha at 2019-02-26 11:12:20:000

Agenus ( AGEN ) is a biotechnology pharmaceutical company with one commercial product and a broad pipeline of potential therapies. It has licensed potential cancer therapies to several larger pharmaceutical companies. The stock plummeted last week, from $3.63 on the prior Friday and to close a… read more...

Agenus Melts Down With Blockchain

via: SeekingAlpha at 2019-02-26 11:12:20:000

Agenus ( AGEN ) is a biotechnology pharmaceutical company with one commercial product and a broad pipeline of potential therapies. It has licensed potential cancer therapies to several larger pharmaceutical companies. The stock plummeted last week, from $3.63 on the prior Friday and to close a… read more...

Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

via: PR Newswire at 2019-02-19 08:30:00:000

LEXINGTON, Mass. , Feb. 19, 2019 / PRNewswire / --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security … read more...

Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

via: PR Newswire at 2019-02-19 08:30:00:000

LEXINGTON, Mass. , Feb. 19, 2019 / PRNewswire / --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security … read more...

Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

via: PR Newswire at 2019-02-19 08:30:00:000

LEXINGTON, Mass. , Feb. 19, 2019 / PRNewswire / --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security … read more...

Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

via: PR Newswire at 2019-02-15 11:41:00:000

LEXINGTON, Mass. , Feb. 15, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST),… read more...

Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

via: PR Newswire at 2019-02-15 11:41:00:000

LEXINGTON, Mass. , Feb. 15, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST),… read more...

Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

via: PR Newswire at 2019-02-15 11:41:00:000

LEXINGTON, Mass. , Feb. 15, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST),… read more...

Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

via: PR Newswire at 2019-02-15 11:41:00:000

LEXINGTON, Mass. , Feb. 15, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today that its Biotech Electronic Security Token (BEST),… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

By Besting Herceptin, The Future Is Bright For MacroGenics

via: SeekingAlpha at 2019-02-11 15:54:44:000

"Marge" Bests Herceptin The treatment of HER2+ breast cancer was revolutionized by approval of Roche's (RHHBY) Herceptin (trastuzumab) in the late 90s. In the past two decades, Herceptin has saved thousands of lives and registered over $75 billion in global sales. Since that time, HER2 h… read more...

By Besting Herceptin, The Future Is Bright For MacroGenics

via: SeekingAlpha at 2019-02-11 15:54:44:000

"Marge" Bests Herceptin The treatment of HER2+ breast cancer was revolutionized by approval of Roche's (RHHBY) Herceptin (trastuzumab) in the late 90s. In the past two decades, Herceptin has saved thousands of lives and registered over $75 billion in global sales. Since that time, HER2 h… read more...

Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

via: PR Newswire at 2019-01-29 08:00:00:000

LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today, the upcoming launch of its Biotech Electronic Sec… read more...

Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

via: PR Newswire at 2019-01-29 08:00:00:000

LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today, the upcoming launch of its Biotech Electronic Sec… read more...

Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.

via: PR Newswire at 2019-01-29 08:00:00:000

NEW YORK , Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Ag… read more...

Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

via: PR Newswire at 2019-01-29 08:00:00:000

LEXINGTON, Mass. , Jan. 29, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , announced today, the upcoming launch of its Biotech Electronic Sec… read more...

Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.

via: PR Newswire at 2019-01-29 08:00:00:000

NEW YORK , Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Ag… read more...

Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.

via: PR Newswire at 2019-01-29 08:00:00:000

NEW YORK , Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Ag… read more...

AAL, LUV among premarket gainers

via: SeekingAlpha at 2019-01-24 09:23:36:000

China Lending (NASDAQ: CLDC ) +35% amid investment, business factoring update. More news on: China Lending Corporation, Teligent, Inc., Xilinx, Inc., Stocks on the move, , Read more … read more...

AAL, LUV among premarket gainers

via: SeekingAlpha at 2019-01-24 09:23:36:000

China Lending (NASDAQ: CLDC ) +35% amid investment, business factoring update. More news on: China Lending Corporation, Teligent, Inc., Xilinx, Inc., Stocks on the move, , Read more … read more...

AAL, LUV among premarket gainers

via: SeekingAlpha at 2019-01-24 09:23:36:000

China Lending (NASDAQ: CLDC ) +35% amid investment, business factoring update. More news on: China Lending Corporation, Teligent, Inc., Xilinx, Inc., Stocks on the move, , Read more … read more...

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

via: PR Newswire at 2019-01-24 08:30:00:000

LEXINGTON, Mass. , Jan. 24, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its immuno-oncology (I-O) partnership deal with Gil… read more...

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

via: PR Newswire at 2019-01-24 08:30:00:000

LEXINGTON, Mass. , Jan. 24, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its immuno-oncology (I-O) partnership deal with Gil… read more...

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

via: PR Newswire at 2019-01-24 08:30:00:000

LEXINGTON, Mass. , Jan. 24, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its immuno-oncology (I-O) partnership deal with Gil… read more...

Momentum Strategies That Continue To Dominate Through January

via: SeekingAlpha at 2019-01-17 16:24:11:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 15% gains through January. These gains again appear to be primarily based on the strength of momentum and forensic negative stock selecti… read more...

Momentum Strategies That Continue To Dominate Through January

via: SeekingAlpha at 2019-01-17 16:24:11:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 15% gains through January. These gains again appear to be primarily based on the strength of momentum and forensic negative stock selecti… read more...

Momentum Strategies That Continue To Dominate Through January

via: SeekingAlpha at 2019-01-17 16:24:11:000

The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 15% gains through January. These gains again appear to be primarily based on the strength of momentum and forensic negative stock selecti… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Where Will M&A Strike Next Across Biotech?

via: SeekingAlpha at 2019-01-09 07:25:36:000

The ruling power is always faced with the question, In such and such circumstances, what would you do?, whereas the opposition is not obliged to take responsibility or make any real decisions. George Orwell The biotech sector had a solid week to kick of… read more...

Where Will M&A Strike Next Across Biotech?

via: SeekingAlpha at 2019-01-09 07:25:36:000

The ruling power is always faced with the question, In such and such circumstances, what would you do?, whereas the opposition is not obliged to take responsibility or make any real decisions. George Orwell The biotech sector had a solid week to kick of… read more...

Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

via: SeekingAlpha at 2019-01-07 10:13:49:000

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...

Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

via: SeekingAlpha at 2019-01-07 10:13:49:000

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...

3 Reasons Biotech Should Rally In 2019

via: SeekingAlpha at 2019-01-04 07:37:10:000

If lies are more comforting to you than facts, you need to get out of your comfort zone. - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se… read more...

3 Reasons Biotech Should Rally In 2019

via: SeekingAlpha at 2019-01-04 07:37:10:000

If lies are more comforting to you than facts, you need to get out of your comfort zone. - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se… read more...

3 Reasons Biotech Should Rally In 2019

via: SeekingAlpha at 2019-01-04 07:37:10:000

If lies are more comforting to you than facts, you need to get out of your comfort zone. - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se… read more...

Agenus Awarded Grant to Enable QS-21 Innovations

via: PR Newswire at 2019-01-03 11:30:00:000

- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21 - Grant to develop an alternative, novel plant cell-culture based method for QS-21 production LEXINGTON, Massachusetts , Jan. 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncolo… read more...

Agenus Gets Hail Mary Cash Infusion From Gilead Sciences

via: SeekingAlpha at 2018-12-26 14:55:45:000

Recently, Agenus Inc. ( AGEN ) announced that it had entered into a partnership with Gilead Sciences ( GILD ) for an immuno-oncology (I-O) pipeline. This partnership will focus on the development and commercialization of up to 5 novel immuno-oncology therapies for Agenus' pipeline. I bel… read more...

Agenus Gets Hail Mary Cash Infusion From Gilead Sciences

via: SeekingAlpha at 2018-12-26 14:55:45:000

Recently, Agenus Inc. ( AGEN ) announced that it had entered into a partnership with Gilead Sciences ( GILD ) for an immuno-oncology (I-O) pipeline. This partnership will focus on the development and commercialization of up to 5 novel immuno-oncology therapies for Agenus' pipeline. I bel… read more...

Agenus Gets Hail Mary Cash Infusion From Gilead Sciences

via: SeekingAlpha at 2018-12-26 14:55:45:000

Recently, Agenus Inc. ( AGEN ) announced that it had entered into a partnership with Gilead Sciences ( GILD ) for an immuno-oncology (I-O) pipeline. This partnership will focus on the development and commercialization of up to 5 novel immuno-oncology therapies for Agenus' pipeline. I bel… read more...

Agenus Wins $1.85 Billion Deal, But Market Cap Is Just $266 Million

via: SeekingAlpha at 2018-12-26 14:45:58:000

Agenus ( AGEN ) is a small cap biotech pharmaceutical company that recently announced a deal potentially worth $1.85 billion with large cap biotech Gilead Sciences ( GILD ). At close on Monday, December 24, Agenus had a stock price of $2.22 and market capitalization of $266 million . I believ… read more...

Agenus Wins $1.85 Billion Deal, But Market Cap Is Just $266 Million

via: SeekingAlpha at 2018-12-26 14:45:58:000

Agenus ( AGEN ) is a small cap biotech pharmaceutical company that recently announced a deal potentially worth $1.85 billion with large cap biotech Gilead Sciences ( GILD ). At close on Monday, December 24, Agenus had a stock price of $2.22 and market capitalization of $266 million . I believ… read more...

Agenus Wins $1.85 Billion Deal, But Market Cap Is Just $266 Million

via: SeekingAlpha at 2018-12-26 14:45:58:000

Agenus ( AGEN ) is a small cap biotech pharmaceutical company that recently announced a deal potentially worth $1.85 billion with large cap biotech Gilead Sciences ( GILD ). At close on Monday, December 24, Agenus had a stock price of $2.22 and market capitalization of $266 million . I believ… read more...

Healthcare & Tech dominate midday movers

via: SeekingAlpha at 2018-12-20 12:40:03:000

Gainers: Inpixon (NASDAQ: INPX ) +37% .Agenus (NASDAQ: AGEN ) +28% . Marin Software (NASDAQ: MRIN ) +18% . Vaxart (NASDAQ: VXRT ) +16% . Digital Ally (NASDAQ: DGLY ) +16% . Neonode (NASDAQ: NEON ) +15% . Fennec Pharmaceuticals (NASDAQ: FENC ) +15% . NF Energy Saving (NAS… read more...

Healthcare & Tech dominate midday movers

via: SeekingAlpha at 2018-12-20 12:40:03:000

Gainers: Inpixon (NASDAQ: INPX ) +37% .Agenus (NASDAQ: AGEN ) +28% . Marin Software (NASDAQ: MRIN ) +18% . Vaxart (NASDAQ: VXRT ) +16% . Digital Ally (NASDAQ: DGLY ) +16% . Neonode (NASDAQ: NEON ) +15% . Fennec Pharmaceuticals (NASDAQ: FENC ) +15% . NF Energy Saving (NAS… read more...

Healthcare & Tech dominate midday movers

via: SeekingAlpha at 2018-12-20 12:40:03:000

Gainers: Inpixon (NASDAQ: INPX ) +37% .Agenus (NASDAQ: AGEN ) +28% . Marin Software (NASDAQ: MRIN ) +18% . Vaxart (NASDAQ: VXRT ) +16% . Digital Ally (NASDAQ: DGLY ) +16% . Neonode (NASDAQ: NEON ) +15% . Fennec Pharmaceuticals (NASDAQ: FENC ) +15% . NF Energy Saving (NAS… read more...

TLRY, AGEN and AU among premarket gainers

via: SeekingAlpha at 2018-12-20 09:23:33:000

Agenus (NASDAQ: AGEN ) +51% on collaborating with Gilead Sciencesto develop five immuno-oncology (I-O) therapies. More news on: Agenus, LM Funding America, Inc., Aimmune Therapeutics, Stocks on the move, , Read more … read more...

TLRY, AGEN and AU among premarket gainers

via: SeekingAlpha at 2018-12-20 09:23:33:000

Agenus (NASDAQ: AGEN ) +51% on collaborating with Gilead Sciencesto develop five immuno-oncology (I-O) therapies. More news on: Agenus, LM Funding America, Inc., Aimmune Therapeutics, Stocks on the move, , Read more … read more...

TLRY, AGEN and AU among premarket gainers

via: SeekingAlpha at 2018-12-20 09:23:33:000

Agenus (NASDAQ: AGEN ) +51% on collaborating with Gilead Sciencesto develop five immuno-oncology (I-O) therapies. More news on: Agenus, LM Funding America, Inc., Aimmune Therapeutics, Stocks on the move, , Read more … read more...

Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket

via: SeekingAlpha at 2018-12-20 07:49:33:000

Agenus (NASDAQ: AGEN ) is up 72% premarket in reaction to its collaboration with Gilead Sciences (NASDAQ: GILD ) to develop five immuno-oncology (I-O) therapies. More news on: Agenus, Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket

via: SeekingAlpha at 2018-12-20 07:49:33:000

Agenus (NASDAQ: AGEN ) is up 72% premarket in reaction to its collaboration with Gilead Sciences (NASDAQ: GILD ) to develop five immuno-oncology (I-O) therapies. More news on: Agenus, Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket

via: SeekingAlpha at 2018-12-20 07:49:33:000

Agenus (NASDAQ: AGEN ) is up 72% premarket in reaction to its collaboration with Gilead Sciences (NASDAQ: GILD ) to develop five immuno-oncology (I-O) therapies. More news on: Agenus, Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

via: PR Newswire at 2018-12-20 07:30:00:000

FOSTER CITY, Calif. and LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to fiv… read more...

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

via: PR Newswire at 2018-12-20 07:30:00:000

FOSTER CITY, Calif. and LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to fiv… read more...

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

via: PR Newswire at 2018-12-20 07:30:00:000

FOSTER CITY, Calif. and LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to fiv… read more...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

via: Business Wire at 2018-12-20 07:23:02:000

-- Agenus Conference Call Scheduled for Today at 8:30 a.m. ET -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five nov… read more...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

via: Business Wire at 2018-12-20 07:23:02:000

-- Agenus Conference Call Scheduled for Today at 8:30 a.m. ET -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five nov… read more...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

via: Business Wire at 2018-12-20 07:23:02:000

-- Agenus Conference Call Scheduled for Today at 8:30 a.m. ET -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five nov… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

via: PR Newswire at 2018-11-13 16:05:00:000

LEXINGTON, Mass. , Nov.13, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of … read more...

Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

via: PR Newswire at 2018-11-13 16:05:00:000

LEXINGTON, Mass. , Nov.13, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of … read more...

Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

via: PR Newswire at 2018-11-13 16:05:00:000

LEXINGTON, Mass. , Nov.13, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of … read more...

Agenus to Present at the 2018 Jefferies London Healthcare Conference

via: PR Newswire at 2018-11-13 11:30:00:000

LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, wi… read more...

Agenus to Present at the 2018 Jefferies London Healthcare Conference

via: PR Newswire at 2018-11-13 11:30:00:000

LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, wi… read more...

Agenus to Present at the 2018 Jefferies London Healthcare Conference

via: PR Newswire at 2018-11-13 11:30:00:000

LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, wi… read more...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

via: PR Newswire at 2018-11-06 17:42:00:000

LEXINGTON, Mass. , Nov. 6,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new data on several of its programs including AutoSy… read more...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

via: PR Newswire at 2018-11-06 17:42:00:000

LEXINGTON, Mass. , Nov. 6,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new data on several of its programs including AutoSy… read more...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

via: PR Newswire at 2018-11-06 17:42:00:000

LEXINGTON, Mass. , Nov. 6,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new data on several of its programs including AutoSy… read more...

Agenus (AGEN) CEO Garo Armen on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 12:24:16:000

Agenus (AGEN) Q3 2018 Earnings Conference Call November 6, 2018 8:30 A.M. ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Head of Clinical Development Christine Klaskin - Vice President of … read more...

Agenus (AGEN) CEO Garo Armen on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 12:24:16:000

Agenus (AGEN) Q3 2018 Earnings Conference Call November 6, 2018 8:30 A.M. ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Head of Clinical Development Christine Klaskin - Vice President of … read more...

Agenus (AGEN) CEO Garo Armen on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 12:24:16:000

Agenus (AGEN) Q3 2018 Earnings Conference Call November 6, 2018 8:30 A.M. ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Head of Clinical Development Christine Klaskin - Vice President of … read more...

Agenus misses by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-06 07:32:33:000

Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.29 misses by $0.04 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Agenus misses by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-06 07:32:33:000

Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.29 misses by $0.04 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Agenus misses by $0.04, beats on revenue

via: SeekingAlpha at 2018-11-06 07:32:33:000

Agenus (NASDAQ: AGEN ): Q3 GAAP EPS of -$0.29 misses by $0.04 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-11-06 07:30:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the third quart… read more...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-11-06 07:30:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the third quart… read more...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-11-06 07:30:00:000

LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the third quart… read more...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-10-31 09:23:00:000

LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on … read more...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-10-31 09:23:00:000

LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on … read more...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-10-31 09:23:00:000

LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on … read more...

Agenus down 7% on PD-1/CTLA-4 program data

via: SeekingAlpha at 2018-10-22 12:10:57:000

Agenus ( AGEN -6.6% ) is down on below-average volume following the presentation of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus down 7% on PD-1/CTLA-4 program data

via: SeekingAlpha at 2018-10-22 12:10:57:000

Agenus ( AGEN -6.6% ) is down on below-average volume following the presentation of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus down 7% on PD-1/CTLA-4 program data

via: SeekingAlpha at 2018-10-22 12:10:57:000

Agenus ( AGEN -6.6% ) is down on below-average volume following the presentation of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

via: PR Newswire at 2018-10-20 07:30:00:000

LEXINGTON, Mass. , Oct. 20 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 2 , presented updated clinical data on its lead CTLA-4 and PD-1 programs today at th… read more...

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

via: PR Newswire at 2018-10-20 07:30:00:000

LEXINGTON, Mass. , Oct. 20 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 2 , presented updated clinical data on its lead CTLA-4 and PD-1 programs today at th… read more...

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

via: PR Newswire at 2018-10-09 09:00:00:000

LEXINGTON, Mass. , Oct. 9,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new clinical data on its lead CTLA-4 and PD-1 programs at the Europ… read more...

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

via: PR Newswire at 2018-10-09 09:00:00:000

LEXINGTON, Mass. , Oct. 9,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new clinical data on its lead CTLA-4 and PD-1 programs at the Europ… read more...

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

via: PR Newswire at 2018-10-09 09:00:00:000

LEXINGTON, Mass. , Oct. 9,2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will present new clinical data on its lead CTLA-4 and PD-1 programs at the Europ… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-09-28 08:38:00:000

LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell , Chief External Affairs Officer at Agenus, w… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

XOMA acquires royalty interest position from Agenus on seven assets developed by Merck and Incyte

via: SeekingAlpha at 2018-09-21 08:12:25:000

XOMA Corporation (NASDAQ: XOMA ) has acquired from Agenus (NASDAQ: AGEN ) a partial interest position in the rights to milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte for $15M. More news on: XOMA Corporation, A… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Closes $15 Million Partial Royalty Monetization With XOMA

via: PR Newswire at 2018-09-21 07:00:00:000

LEXINGTON, Mass. , Sept. 21, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Cor… read more...

Agenus Receives Milestone Payment from Incyte

via: PR Newswire at 2018-09-17 09:00:00:000

LEXINGTON, Mass. , Sept. 17, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today receipt of a cash milestone from Incyte for the initiation… read more...

Agenus Receives Milestone Payment from Incyte

via: PR Newswire at 2018-09-17 09:00:00:000

LEXINGTON, Mass. , Sept. 17, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today receipt of a cash milestone from Incyte for the initiation… read more...

Agenus Receives Milestone Payment from Incyte

via: PR Newswire at 2018-09-17 09:00:00:000

LEXINGTON, Mass. , Sept. 17, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today receipt of a cash milestone from Incyte for the initiation… read more...

Bulletproof Investing Performance Update, Week 41

via: SeekingAlpha at 2018-09-13 12:43:04:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 41 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Bulletproof Investing Performance Update, Week 41

via: SeekingAlpha at 2018-09-13 12:43:04:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 41 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Bulletproof Investing Performance Update, Week 41

via: SeekingAlpha at 2018-09-13 12:43:04:000

Safety first: NASCAR driver Johanna Long and her helmet (via Autowise ). Bulletproof Investing: Week 41 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is a… read more...

Surviving A Bad Stock Pick: Agenus

via: SeekingAlpha at 2018-09-12 14:16:16:000

Image via Agenus's website . Surviving A Bad Pick In A Concentrated Portfolio Agenus ( AGEN ) was one of 5 underlying securities I included in a $100,000 hedged portfolio for my Bulletproof Investing subscribers on March 8th, and AGEN did terribly over the next several months, as you c… read more...

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

via: PR Newswire at 2018-09-05 19:34:00:000

LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ --AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa , Senior Dir… read more...

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

via: PR Newswire at 2018-09-05 19:34:00:000

LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ --AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa , Senior Dir… read more...

AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

via: PR Newswire at 2018-09-05 19:34:00:000

LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ --AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa , Senior Dir… read more...

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

via: PR Newswire at 2018-09-04 09:57:00:000

LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and Extern… read more...

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

via: PR Newswire at 2018-09-04 09:57:00:000

LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and Extern… read more...

Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

via: PR Newswire at 2018-09-04 09:57:00:000

LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and Extern… read more...

Agenus: Buy Or Sell?

via: SeekingAlpha at 2018-08-26 11:46:58:000

Agenus ( AGEN ) was founded in 1994 and is based in Lexington, MA. Shares have risen >30% last week since the idea was published to the subscribers of Vasuda Healthcare Analytics, marketplace service. Bull's case: (R&D pipeline, source company website) The company has a diverse… read more...

Agenus: Buy Or Sell?

via: SeekingAlpha at 2018-08-26 11:46:58:000

Agenus ( AGEN ) was founded in 1994 and is based in Lexington, MA. Shares have risen >30% last week since the idea was published to the subscribers of Vasuda Healthcare Analytics, marketplace service. Bull's case: (R&D pipeline, source company website) The company has a diverse… read more...

Agenus: Buy Or Sell?

via: SeekingAlpha at 2018-08-26 11:46:58:000

Agenus ( AGEN ) was founded in 1994 and is based in Lexington, MA. Shares have risen >30% last week since the idea was published to the subscribers of Vasuda Healthcare Analytics, marketplace service. Bull's case: (R&D pipeline, source company website) The company has a diverse… read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/22/2018)

via: SeekingAlpha at 2018-08-22 12:45:18:000

Gainers: YECO +56% . NEWA +30% . EXAS +26% . MYND +22% . PSTG +17% . AGEN +14% . LZB +12% . ADMP +12% . MYGN +11% . EPE +11% . More news on: Yulong Eco-Materials, Newater Technology, Inc., EXACT Sciences Corporation, Stocks on the move, , Read more … ... read more...

Midday Gainers / Losers (08/21/2018)

via: SeekingAlpha at 2018-08-21 12:55:53:000

Gainers: TAT +21% . KOSS +21% . UXIN +18% . LLEX +17% . AGFS +16% . AGEN +16% . RNN +16% . BLFS +15% . PINC +15% . GSB +15% . Losers: SEAC -42% . NEWA -38% . SITO -17% . GRIN -13% . COCP -12% . DAKT -10% . COTY -10% . BOSC -10% . … read more...

Agenus earns second $4M milestone payment from Merck

via: SeekingAlpha at 2018-08-15 13:44:24:000

Agenus ( AGEN -4.7% ) announces that it has received a $4M milestone payment from Merck ( MRK +0.5% ) triggered by the initiation of a Phase 1 clinical trial of an undisclosed antibody discovered by Agenus. More news on: Agenus, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Agenus earns second $4M milestone payment from Merck

via: SeekingAlpha at 2018-08-15 13:44:24:000

Agenus ( AGEN -4.7% ) announces that it has received a $4M milestone payment from Merck ( MRK +0.5% ) triggered by the initiation of a Phase 1 clinical trial of an undisclosed antibody discovered by Agenus. More news on: Agenus, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Agenus earns second $4M milestone payment from Merck

via: SeekingAlpha at 2018-08-15 13:44:24:000

Agenus ( AGEN -4.7% ) announces that it has received a $4M milestone payment from Merck ( MRK +0.5% ) triggered by the initiation of a Phase 1 clinical trial of an undisclosed antibody discovered by Agenus. More news on: Agenus, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Agenus Receives Second Milestone Payment from Merck

via: PR Newswire at 2018-08-15 13:22:00:000

LEXINGTON, Mass. , Aug. 15, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Merck, known as MSD outside the United States and Can… read more...

Agenus Receives Second Milestone Payment from Merck

via: PR Newswire at 2018-08-15 13:22:00:000

LEXINGTON, Mass. , Aug. 15, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Merck, known as MSD outside the United States and Can… read more...

Agenus Receives Second Milestone Payment from Merck

via: PR Newswire at 2018-08-15 13:22:00:000

LEXINGTON, Mass. , Aug. 15, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Merck, known as MSD outside the United States and Can… read more...

Agenus (AGEN) CEO Garo Armen on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 14:32:06:000

Agenus (AGEN) Q2 2018 Results Earnings Conference Call August 9, 2018, 08:30 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Sunil Gupta - Head of Regulatory and Pharmacovigilance Christine Klaskin - VP of Finance Anal… read more...

Agenus (AGEN) CEO Garo Armen on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 14:32:06:000

Agenus (AGEN) Q2 2018 Results Earnings Conference Call August 9, 2018, 08:30 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Sunil Gupta - Head of Regulatory and Pharmacovigilance Christine Klaskin - VP of Finance Anal… read more...

Agenus (AGEN) CEO Garo Armen on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-09 14:32:06:000

Agenus (AGEN) Q2 2018 Results Earnings Conference Call August 9, 2018, 08:30 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Sunil Gupta - Head of Regulatory and Pharmacovigilance Christine Klaskin - VP of Finance Anal… read more...

Agenus up 2% premarket on Q2 results

via: SeekingAlpha at 2018-08-09 09:01:50:000

Agenus ( AGEN ) Q2 results : Revenues: $10.5M. More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Agenus up 2% premarket on Q2 results

via: SeekingAlpha at 2018-08-09 09:01:50:000

Agenus ( AGEN ) Q2 results : Revenues: $10.5M. More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Agenus up 2% premarket on Q2 results

via: SeekingAlpha at 2018-08-09 09:01:50:000

Agenus ( AGEN ) Q2 results : Revenues: $10.5M. More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more … read more...

Agenus beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-09 08:03:25:000

Agenus (NASDAQ: AGEN ): Q2 EPS of -$0.24 beats by $0.16 . More news on: Agenus, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Agenus beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-09 08:03:25:000

Agenus (NASDAQ: AGEN ): Q2 EPS of -$0.24 beats by $0.16 . More news on: Agenus, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Agenus beats by $0.16, beats on revenue

via: SeekingAlpha at 2018-08-09 08:03:25:000

Agenus (NASDAQ: AGEN ): Q2 EPS of -$0.24 beats by $0.16 . More news on: Agenus, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more … read more...

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 08:00:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the second quar… read more...

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 08:00:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the second quar… read more...

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-08-09 08:00:00:000

LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the second quar… read more...

Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-08-02 14:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on … read more...

Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-08-02 14:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on … read more...

Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-08-02 14:00:00:000

LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on … read more...

Agenus Illustrates Dilution And Non-Dilution Perils

via: SeekingAlpha at 2018-07-26 10:19:14:000

Agenus (AGEN) set a new 52-week low on July 24, closing at $1.94. It is also at a multi-year low. This small-cap biotech has a royalty interest in the new shingles vaccine Shingrix . It has a pipeline of immune-oncology drugs in the clinic, two licensed to Incyte (INCY). What went wrong and c… read more...

Agenus Illustrates Dilution And Non-Dilution Perils

via: SeekingAlpha at 2018-07-26 10:19:14:000

Agenus (AGEN) set a new 52-week low on July 24, closing at $1.94. It is also at a multi-year low. This small-cap biotech has a royalty interest in the new shingles vaccine Shingrix . It has a pipeline of immune-oncology drugs in the clinic, two licensed to Incyte (INCY). What went wrong and c… read more...

Agenus Illustrates Dilution And Non-Dilution Perils

via: SeekingAlpha at 2018-07-26 10:19:14:000

Agenus (AGEN) set a new 52-week low on July 24, closing at $1.94. It is also at a multi-year low. This small-cap biotech has a royalty interest in the new shingles vaccine Shingrix . It has a pipeline of immune-oncology drugs in the clinic, two licensed to Incyte (INCY). What went wrong and c… read more...

Agenus Appoints Regulatory and Clinical Heads

via: PR Newswire at 2018-07-16 08:37:00:000

LEXINGTON, Mass. , July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies 1 , today announced the appointment of I-O dr… read more...

Agenus Appoints Regulatory and Clinical Heads

via: PR Newswire at 2018-07-16 08:37:00:000

LEXINGTON, Mass. , July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies 1 , today announced the appointment of I-O dr… read more...

Agenus Appoints Regulatory and Clinical Heads

via: PR Newswire at 2018-07-16 08:37:00:000

LEXINGTON, Mass. , July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies 1 , today announced the appointment of I-O dr… read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Agenus to Webcast Annual Meeting of Stockholders

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites investors and the general public to attend its Annual Meeting of Stockholde… read more...

Agenus to Webcast Annual Meeting of Stockholders

via: PR Newswire at 2018-06-20 08:00:00:000

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites investors and the general public to attend its Annual Meeting of Stockholde… read more...

Avrobio Aims For $75 Million U.S. IPO

via: SeekingAlpha at 2018-06-12 12:47:29:000

Quick Take Avrobio ( AVRO ) intends to sell shares of its common stock to raise $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing lentiviral-based gene therapies with the potential to treat rare diseases in a single dose. AVRO has a… read more...

Avrobio Aims For $75 Million U.S. IPO

via: SeekingAlpha at 2018-06-12 12:47:29:000

Quick Take Avrobio ( AVRO ) intends to sell shares of its common stock to raise $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing lentiviral-based gene therapies with the potential to treat rare diseases in a single dose. AVRO has a… read more...

Avrobio Aims For $75 Million U.S. IPO

via: SeekingAlpha at 2018-06-12 12:47:29:000

Quick Take Avrobio ( AVRO ) intends to sell shares of its common stock to raise $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing lentiviral-based gene therapies with the potential to treat rare diseases in a single dose. AVRO has a… read more...

Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

via: PR Newswire at 2018-06-12 08:30:00:000

LEXINGTON, Mass. , June 12, 2018 /PRNewswire/ --A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discov… read more...

Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

via: PR Newswire at 2018-06-12 08:30:00:000

LEXINGTON, Mass. , June 12, 2018 /PRNewswire/ --A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discov… read more...

Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

via: PR Newswire at 2018-06-12 08:30:00:000

LEXINGTON, Mass. , June 12, 2018 /PRNewswire/ --A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4. Agenus has applied this discov… read more...

Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-06-06 13:00:00:000

LEXINGTON, Mass. , June 6 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and External Affair… read more...

Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-06-06 13:00:00:000

LEXINGTON, Mass. , June 6 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and External Affair… read more...

Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

via: PR Newswire at 2018-06-06 13:00:00:000

LEXINGTON, Mass. , June 6 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell , Ph.D., Chief Communications and External Affair… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash

via: SeekingAlpha at 2018-05-24 09:50:21:000

In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus: Buy, Sell Or Hold?

via: SeekingAlpha at 2018-05-18 12:37:13:000

"An adventure is only an inconvenience rightly considered. An inconvenience is only an adventure wrongly considered." - G.K. Chesterton I have gotten several questions around a ~$3.50 biotech concern that I have not discussed in quite some time of late. The stock has been weak and has fall… read more...

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

via: PR Newswire at 2018-05-17 13:37:00:000

LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-… read more...

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

via: PR Newswire at 2018-05-17 13:37:00:000

LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-… read more...

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

via: PR Newswire at 2018-05-17 13:37:00:000

LEXINGTON, Mass. , May 17 , 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-… read more...

Agenus -6.5% on at-the-market sales deal for 20M shares

via: SeekingAlpha at 2018-05-11 17:56:03:000

Biotech firm Agenus (NASDAQ: AGEN ) is 6.5% lower postmarket after a filing notes it's entered an at-the-market sales deal covering up to 20M shares. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus -6.5% on at-the-market sales deal for 20M shares

via: SeekingAlpha at 2018-05-11 17:56:03:000

Biotech firm Agenus (NASDAQ: AGEN ) is 6.5% lower postmarket after a filing notes it's entered an at-the-market sales deal covering up to 20M shares. More news on: Agenus, Healthcare stocks news, Stocks on the move, Read more … read more...

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

via: SeekingAlpha at 2018-05-08 03:34:11:000

Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu… read more...

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

via: SeekingAlpha at 2018-05-08 03:34:11:000

Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu… read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-07 14:54:01:000

Agenus (AGEN) Q1 2018 Earnings Conference Call May 7, 2018, 11:00 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Christine Klaskin - VP of Finance Analysts Matt Philips - William Blair Presentation Operator … read more...

Agenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-07 14:54:01:000

Agenus (AGEN) Q1 2018 Earnings Conference Call May 7, 2018, 11:00 AM ET Executives Jennifer Buell - Head-Communications and External Affairs Garo Armen - Chairman and CEO Christine Klaskin - VP of Finance Analysts Matt Philips - William Blair Presentation Operator … read more...

Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston

via: PR Newswire at 2018-05-07 13:00:00:000

LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen , Ph.D., Chairman & CEO, and Jennifer Buell , Ph…. read more...

Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston

via: PR Newswire at 2018-05-07 13:00:00:000

LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen , Ph.D., Chairman & CEO, and Jennifer Buell , Ph…. read more...

Agenus reports Q1 results; provides milestones for 2018

via: SeekingAlpha at 2018-05-07 09:26:07:000

Agenus ( AGEN ) Q1 results : R&D Expense: $29.4M (-9.8%); SG&A: $10.7M (-7.8%); Net Loss: ($54.3M); Loss Per Share: ($0.53); Quick Assets: $52.3M (-13.1%). More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus reports Q1 results; provides milestones for 2018

via: SeekingAlpha at 2018-05-07 09:26:07:000

Agenus ( AGEN ) Q1 results : R&D Expense: $29.4M (-9.8%); SG&A: $10.7M (-7.8%); Net Loss: ($54.3M); Loss Per Share: ($0.53); Quick Assets: $52.3M (-13.1%). More news on: Agenus, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Agenus misses by $0.23

via: SeekingAlpha at 2018-05-07 09:07:57:000

Agenus (NASDAQ: AGEN ): Q1 EPS of -$0.53 misses by $0.23 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus misses by $0.23

via: SeekingAlpha at 2018-05-07 09:07:57:000

Agenus (NASDAQ: AGEN ): Q1 EPS of -$0.53 misses by $0.23 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-05-07 09:00:00:000

LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the first quarter end… read more...

Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update

via: PR Newswire at 2018-05-07 09:00:00:000

LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the first quarter end… read more...

Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-05-03 09:00:00:000

LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday,… read more...

Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast

via: PR Newswire at 2018-05-03 09:00:00:000

LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday,… read more...

AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA

via: PR Newswire at 2018-05-01 08:00:00:000

LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz , Vice President, Head o… read more...

AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA

via: PR Newswire at 2018-05-01 08:00:00:000

LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz , Vice President, Head o… read more...

Evelo Biosciences To Raise $85 Million In IPO

via: SeekingAlpha at 2018-04-30 12:02:42:000

Quick Take Evelo Biosciences ( EVLO ) intends to raise $85 million in an IPO from the sale of its common stock. The company is developing a pipeline of monoclonal microbials that act on the gut-body complex to treat inflammatory diseases and cancers. EVLO is working in a nascent and … read more...

Agenus gets modust bump from Bristol-Myers' success with Opdivo/Yervoy in first-line NSCLC, shares up 3% premarket

via: SeekingAlpha at 2018-02-05 08:12:44:000

Agenus (NASDAQ: AGEN ) is up 3% premarket modestly higher volume in response to Bristol-Myers Squibb's announcement of positive results from a Phase 3 clinical trial evaluating the combination of Opdivo, an anti-PD-1 antibody, and Yervoy, an anti-CTLA-4 antibody, in first-line no… read more...

Agenus gets modust bump from Bristol-Myers' success with Opdivo/Yervoy in first-line NSCLC, shares up 3% premarket

via: SeekingAlpha at 2018-02-05 08:12:44:000

Agenus (NASDAQ: AGEN ) is up 3% premarket modestly higher volume in response to Bristol-Myers Squibb's announcement of positive results from a Phase 3 clinical trial evaluating the combination of Opdivo, an anti-PD-1 antibody, and Yervoy, an anti-CTLA-4 antibody, in first-line no… read more...

Agenus gets modust bump from Bristol-Myers' success with Opdivo/Yervoy in first-line NSCLC, shares up 3% premarket

via: SeekingAlpha at 2018-02-05 08:12:44:000

Agenus (NASDAQ: AGEN ) is up 3% premarket modestly higher volume in response to Bristol-Myers Squibb's announcement of positive results from a Phase 3 clinical trial evaluating the combination of Opdivo, an anti-PD-1 antibody, and Yervoy, an anti-CTLA-4 antibody, in first-line no… read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Yet-to-be-released White House infrastructure plan published

via: SeekingAlpha at 2018-01-22 18:24:37:000

Axios publishes what it says is a draft copy of the Trump administration's infrastructure plan; it contains no specific dollar amounts for any of the initiatives. More news on: Caterpillar Inc., Cemex, S.A.B. de C.V., Martin Marietta Materials Inc., Read more … read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

via: PR Newswire at 2018-01-22 10:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN203… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-22 07:00:00:000

LEXINGTON, Mass. , Jan. 22, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Part… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-01-21 02:53:39:000

Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again

via: SeekingAlpha at 2018-01-09 11:02:20:000

Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am

via: SeekingAlpha at 2018-01-08 09:21:31:000

SPCB +62% in process of developing various cryptocurrency capabilities for its SuperPay secure mobile money suite. More news on: SuperCom, Ltd., MySize Inc., LightInTheBox Holding Co., Ltd., Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus inks $230M royalty monetization deal; shares up 14% premarket

via: SeekingAlpha at 2018-01-08 09:19:36:000

Agenus (NASDAQ: AGEN ) is up 14% premarket on robust volume in response to its monetization deal with HealthCare Royalty Partners (HCR) for vaccine-related QS-21 royalties. More news on: Agenus, GlaxoSmithKline, Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners

via: PR Newswire at 2018-01-08 08:32:00:000

LEXINGTON, Mass. , Jan. 8, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The tr… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018

via: PR Newswire at 2018-01-04 07:30:00:000

LEXINGTON, Mass. , Jan. 4, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle , Head of Translational Medicine and Bioinformatics , will participate in… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings

via: PR Newswire at 2018-01-03 07:00:00:000

LEXINGTON, Mass. , Jan. 3, 2018 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will s… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX